Figures computed from official regulatory filings — .
Analysttarget 5.45 USD (+555%) · consensus 4.47/5 · 12 buy · 3 hold · 0 sell
Ownershipinsiders 12.47% · institutions 88.56% · short 26.8% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Compass Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
52 buys7 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Lerner Neiltrack record | Buy | $18.4K | conv 38 |
| Lerner Neiltrack record | Buy | $2.8K | conv 41Unusual size | SEC |
| Lerner Neiltrack record | Buy | $28.4K | conv 47First in 12mo | SEC |
| Anderman Jonathan | Buy | $47.3K | conv 66First in 12mo | SEC |
| Lerner Neiltrack record | Award | $28.4K | SEC |
| Schuetz Thomas J.track record | Other | $239.2K | SEC |
| Schuetz Thomas J.track record | Other | $250.3K | SEC |
| Chiniara Ellen | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Boylan James P | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Schuetz Thomas J.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Anderman Jonathan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| LINDAHL RICHARD S | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Shin Barry | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lerner Neiltrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GORDON CARL Ltrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Prasad Arjun | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Anderman Jonathan | Award | $775.5K | SEC |
| Ferneau Philip | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sirard Cynthia | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| GRAY MARY ANN | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Schuetz Thomas J.track record | Award | $1.3M | Unusual size | SEC |
| Shin Barry | Award | $646.3K | Unusual size | SEC |
| Lerner Neiltrack record | Award | $323.1K | SEC |
| Schuetz Thomas J.track record | Other | $212.6K | SEC |
| Schuetz Thomas J.track record | Buy | $21.1K | conv 50ClusterFirst in 12mo | SEC |